• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

低密度脂蛋白受体缺陷和载脂蛋白E缺陷小鼠的动脉粥样硬化进展与纤溶酶原激活物抑制剂-1的基因改变无关。

Atherosclerosis progression in LDL receptor-deficient and apolipoprotein E-deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1.

作者信息

Sjöland H, Eitzman D T, Gordon D, Westrick R, Nabel E G, Ginsburg D

机构信息

Division of Cardiology, Department of Internal Medicine, Howard Hughes Medical Institute, University of Michigan Medical Center, Ann Arbor 48109-0644, USA.

出版信息

Arterioscler Thromb Vasc Biol. 2000 Mar;20(3):846-52. doi: 10.1161/01.atv.20.3.846.

DOI:10.1161/01.atv.20.3.846
PMID:10712412
Abstract

Impaired fibrinolysis has been linked to atherosclerosis in a number of experimental and clinical studies. Plasminogen activator inhibitor type 1 (PAI-1) is the primary inhibitor of plasminogen activation and has been proposed to promote atherosclerosis by facilitating fibrin deposition within developing lesions. We examined the contribution of PAI-1 to disease progression in 2 established mouse models of atherosclerosis. Mice lacking apolipoprotein E (apoE-/-) and mice lacking the low density lipoprotein receptor (LDLR-/-) were crossbred with transgenic mice overexpressing PAI-1 (resulting in PAI-1 Tg(+)/apoE-/- and PAI-1 Tg(+)/LDLR-/-, respectively) or were crossbred with mice completely deficient in PAI-1 gene expression (resulting in PAI-1-/-/apoE-/- and PAI-1-/-/LDLR-/-, respectively). All animals were placed on a western diet (21% fat and 0.15% cholesterol) at 4 weeks of age and analyzed for the extent of atherosclerosis after an additional 6, 15, or 30 weeks. Intimal and medial areas were determined by computer-assisted morphometric analysis of standardized microscopic sections from the base of the aorta. Atherosclerotic lesions were also characterized by histochemical analyses with the use of markers for smooth muscle cells, macrophages, and fibrin deposition. Typical atherosclerotic lesions were observed in all experimental animals, with greater severity at the later time points and generally more extensive lesions in apoE-/- than in comparable LDLR-/- mice. No significant differences in lesion size or histological appearance were observed among PAI-1-/-, PAI-1 Tg(+), or PAI-1 wild-type mice at any of the time points on either the apoE-/- or LDLR-/- genetic background. We conclude that genetic modification of PAI-1 expression does not significantly alter the progression of atherosclerosis in either of these well-established mouse models. These results suggest that fibrinolytic balance (as well as the potential contribution of PAI-1 to the regulation of cell migration) plays only a limited role in the pathogenesis of the simple atherosclerotic lesions observed in the mouse.

摘要

在多项实验和临床研究中,纤维蛋白溶解功能受损与动脉粥样硬化相关。纤溶酶原激活物抑制剂1(PAI-1)是纤溶酶原激活的主要抑制剂,有人提出它通过促进纤维蛋白在发展中的病变内沉积来促进动脉粥样硬化。我们在两种已建立的动脉粥样硬化小鼠模型中研究了PAI-1对疾病进展的影响。将缺乏载脂蛋白E的小鼠(apoE-/-)和缺乏低密度脂蛋白受体的小鼠(LDLR-/-)分别与过表达PAI-1的转基因小鼠杂交(分别产生PAI-1 Tg(+)/apoE-/-和PAI-1 Tg(+)/LDLR-/-),或者与完全缺乏PAI-1基因表达的小鼠杂交(分别产生PAI-1-/-/apoE-/-和PAI-1-/-/LDLR-/-)。所有动物在4周龄时开始给予西式饮食(21%脂肪和0.15%胆固醇),并在另外6、15或30周后分析动脉粥样硬化的程度。通过对主动脉基部标准化显微切片进行计算机辅助形态测量分析来确定内膜和中膜面积。还通过使用平滑肌细胞、巨噬细胞和纤维蛋白沉积标记物的组织化学分析来表征动脉粥样硬化病变。在所有实验动物中均观察到典型的动脉粥样硬化病变,在后期时间点病变更严重,并且在apoE-/-小鼠中病变通常比在可比的LDLR-/-小鼠中更广泛。在apoE-/-或LDLR-/-遗传背景下的任何时间点,PAI-1-/-、PAI-1 Tg(+)或PAI-1野生型小鼠之间在病变大小或组织学外观上均未观察到显著差异。我们得出结论,在这两种已建立的小鼠模型中,PAI-1表达的基因修饰均未显著改变动脉粥样硬化的进展。这些结果表明,纤维蛋白溶解平衡(以及PAI-1对细胞迁移调节的潜在作用)在小鼠中观察到的简单动脉粥样硬化病变的发病机制中仅起有限作用。

相似文献

1
Atherosclerosis progression in LDL receptor-deficient and apolipoprotein E-deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1.低密度脂蛋白受体缺陷和载脂蛋白E缺陷小鼠的动脉粥样硬化进展与纤溶酶原激活物抑制剂-1的基因改变无关。
Arterioscler Thromb Vasc Biol. 2000 Mar;20(3):846-52. doi: 10.1161/01.atv.20.3.846.
2
Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery.纤溶酶原激活物抑制剂-1缺乏可预防小鼠颈动脉粥样硬化进展。
Blood. 2000 Dec 15;96(13):4212-5.
3
Plasminogen activator inhibitor type 1 enhances neointima formation after oxidative vascular injury in atherosclerosis-prone mice.1型纤溶酶原激活物抑制剂可增强易患动脉粥样硬化小鼠氧化血管损伤后的内膜增生。
Circulation. 2001 Jun 26;103(25):3105-10. doi: 10.1161/01.cir.103.25.3105.
4
Attenuation of neointimal vascular smooth muscle cellularity in atheroma by plasminogen activator inhibitor type 1 (PAI-1).1型纤溶酶原激活物抑制剂(PAI-1)对动脉粥样硬化中新生内膜血管平滑肌细胞数量的抑制作用。
J Histochem Cytochem. 2004 Aug;52(8):1091-9. doi: 10.1369/jhc.4A6260.2004.
5
Atherosclerosis, vascular remodeling, and impairment of endothelium-dependent relaxation in genetically altered hyperlipidemic mice.基因改变的高脂血症小鼠的动脉粥样硬化、血管重塑及内皮依赖性舒张功能受损
Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2333-40. doi: 10.1161/01.atv.17.11.2333.
6
Enhanced thrombosis in atherosclerosis-prone mice is associated with increased arterial expression of plasminogen activator inhibitor-1.动脉粥样硬化易患小鼠中血栓形成增强与纤溶酶原激活物抑制剂-1的动脉表达增加有关。
Arterioscler Thromb Vasc Biol. 2003 Nov 1;23(11):2097-103. doi: 10.1161/01.ATV.0000097766.36623.DF. Epub 2003 Sep 25.
7
Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice.纤溶酶原激活物抑制剂-1的缺失促进载脂蛋白E缺陷小鼠中晚期动脉粥样硬化斑块的生长和异常基质重塑。
Arterioscler Thromb Vasc Biol. 2002 Mar 1;22(3):499-505. doi: 10.1161/hq0302.104529.
8
Atherogenic and pulmonary responses of ApoE- and LDL receptor-deficient mice to sidestream cigarette smoke.载脂蛋白 E 缺陷型和 LDL 受体缺陷型小鼠对侧流香烟烟雾的动脉粥样硬化和肺部反应。
Toxicology. 2012 Sep 28;299(2-3):133-8. doi: 10.1016/j.tox.2012.05.015. Epub 2012 Jun 1.
9
Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E.载脂蛋白E降低异前列腺素水平并使晚期动脉粥样硬化消退。
J Biol Chem. 2001 Jan 5;276(1):261-6. doi: 10.1074/jbc.M003324200.
10
[Expressions of atherosclerosis-related genes in aorta in young apoE/LDLR double knockout mice].[年轻载脂蛋白E/低密度脂蛋白受体双敲除小鼠主动脉中动脉粥样硬化相关基因的表达]
Sheng Li Xue Bao. 2008 Feb 25;60(1):43-50.

引用本文的文献

1
A Web of Challenges: The Therapeutic Struggle to Target NETs in Disease.挑战之网:针对疾病中神经内分泌肿瘤的治疗难题
Int J Mol Sci. 2025 May 16;26(10):4773. doi: 10.3390/ijms26104773.
2
Tale of two systems: the intertwining duality of fibrinolysis and lipoprotein metabolism.两个系统的故事:纤溶与脂蛋白代谢的交织双重性。
J Thromb Haemost. 2023 Oct;21(10):2679-2696. doi: 10.1016/j.jtha.2023.08.004. Epub 2023 Aug 12.
3
Atherogenesis in and Mice with a Genetically Resistant Background.载脂蛋白 E 基因敲除小鼠和载脂蛋白 E 基因敲入小鼠的动脉粥样硬化形成。
Cells. 2023 Apr 26;12(9):1255. doi: 10.3390/cells12091255.
4
Adipokines, adiposity, and atherosclerosis.脂联素、肥胖与动脉粥样硬化。
Cell Mol Life Sci. 2022 May 3;79(5):272. doi: 10.1007/s00018-022-04286-2.
5
A Serpin With a Finger in Many PAIs: PAI-1's Central Function in Thromboinflammation and Cardiovascular Disease.一种在多种蛋白酶抑制物中起作用的丝氨酸蛋白酶抑制剂:纤溶酶原激活物抑制剂-1在血栓炎症和心血管疾病中的核心作用
Front Cardiovasc Med. 2021 Apr 16;8:653655. doi: 10.3389/fcvm.2021.653655. eCollection 2021.
6
Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.心血管疾病中靶向纤溶酶原激活物抑制剂-1:纤溶酶原激活物抑制剂-1功能及抑制作用的结构见解
Front Cardiovasc Med. 2020 Dec 22;7:622473. doi: 10.3389/fcvm.2020.622473. eCollection 2020.
7
Mouse models of atherosclerosis and their suitability for the study of myocardial infarction.动脉粥样硬化的小鼠模型及其在心肌梗死研究中的适用性。
Basic Res Cardiol. 2020 Nov 30;115(6):73. doi: 10.1007/s00395-020-00829-5.
8
Drug Targeting of Plasminogen Activator Inhibitor-1 Inhibits Metabolic Dysfunction and Atherosclerosis in a Murine Model of Metabolic Syndrome.纤溶酶原激活物抑制剂-1 的药物靶向抑制代谢综合征小鼠模型的代谢功能障碍和动脉粥样硬化。
Arterioscler Thromb Vasc Biol. 2020 Jun;40(6):1479-1490. doi: 10.1161/ATVBAHA.119.313775. Epub 2020 Apr 9.
9
Combined but not single treatment with ethinylestradiol/levonorgestrel and spironolactone reduces plasminogen activator inhibitor-1 in insulin-resistant ovariectomised rats.雌二醇/左炔诺孕酮与螺内酯联合而非单独治疗可降低胰岛素抵抗去卵巢大鼠的纤溶酶原激活物抑制剂-1。
J Renin Angiotensin Aldosterone Syst. 2019 Oct-Dec;20(4):1470320319895933. doi: 10.1177/1470320319895933.
10
Visualization of endothelial barrier damage prior to formation of atherosclerotic plaques.在动脉粥样硬化斑块形成之前可视化内皮屏障损伤。
Histochem Cell Biol. 2017 Aug;148(2):117-127. doi: 10.1007/s00418-017-1562-8. Epub 2017 Mar 25.